Certara Services Archives

On-Demand Webinar

Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…

CertaraMay 13, 2019

Blog

Trends for Market Access, HEOR, and Real World Evidence

This blog reviews trends for using health economics and outcomes research and real-world evidence to…

CertaraMay 10, 2019

Blog

Real World Evidence Marches Forward in Drug Development

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…

CertaraMarch 20, 2019

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

CertaraJune 2, 2018

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

CertaraFebruary 15, 2018

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

CertaraAugust 24, 2017

White Paper

Model-based Meta-analysis: An Innovative Methodology Comes of Age

MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…

CertaraJuly 14, 2016

Publication

Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis

The objective of this study was to assess the relationship between short-term and long-term treatment…

CertaraJuly 1, 2016

Publication

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

Gastric emptying (GE) is often reported to be slower and more irregular in premature neonates than…

CertaraMay 1, 2015

Publication

A Model-based Dose-response Meta-analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma

PURPOSE: To characterize dose and response for intraocular pressure (IOP) reduction and incidence of hyperemia…

CertaraMay 1, 2015

Certara Services

Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement

Trends for Market Access, HEOR, and Real World Evidence

Real World Evidence Marches Forward in Drug Development

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Model-based Meta-analysis: An Innovative Methodology Comes of Age

Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

A Model-based Dose-response Meta-analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma

Newsletter sign up

Quick links

Solutions

Contact